查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1864534

脑和脊髓癌市场：2025-2032年全球预测（按癌症类型、治疗方法、患者年龄层、最终用户和通路）

Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，脑部和脊髓肿瘤治疗市场将成长至 63.3 亿美元，复合年增长率为 5.97%。

关键市场统计数据
基准年 2024 39.8亿美元
预计年份：2025年 42.1亿美元
预测年份 2032 63.3亿美元
复合年增长率 (%) 5.97%

策略性地介绍临床、监管和营运因素的融合如何重塑神经肿瘤学的诊断、治疗和护理服务。

本执行摘要摘要了影响脑部和脊髓肿瘤治疗的最重要临床、运作和策略主题。分子特征分析和精准医学的进步正在重新定义诊断路径，同时也为治疗决策过程带来了新的复杂性。不断发展的医疗服务模式以及多学科协作日益重要的作用，也在改变患者对诊断、治疗和復健的体验。

监管路径也同步发展，加速核准和适应性试验设计使患者能够更早获得创新治疗方法。这些创新伴随着对真实世界证据和核准后数据日益增长的需求，相关人员必须将其纳入生命週期规划。同样重要的是系统层面的因素，例如供应链脆弱性、人才短缺以及支付政策的争议，这些因素都会影响创新成果的转换应用。

总体而言，这些趋势既为商业团队、临床领导者和支付方带来了机会，也带来了责任。本摘要係统地阐述了变革性转变、关税主导的供应考量、细分市场洞察、区域差异和竞争行为，旨在为神经肿瘤生态系统的策略和投资重点提供参考。

本书冷静地检验了正在重塑神经肿瘤治疗模式和相关人员期望的变革性科学、医疗服务和政策变化。

治疗创新是推动改变的最主要动力，标靶治疗药物、免疫疗法和先进的放射治疗方法正在改变传统的治疗流程。精准诊断技术将患者按分子特征分层，从而实现更个人化的治疗计划，同时也需要整合生物标记检测基础设施和新的诊疗路径。这些科学进步与改进的手术流程和设备相辅相成，包括更安全的手术技术和高精度立体定位系统，这些共同降低了併发症的风险，并拓展了治疗选择的范围。

医疗服务体係正经历着一场同步的变革。多学科肿瘤咨询、远端医疗和分散式治疗方案正在扩大医疗服务的覆盖范围，同时也对传统的以医院为中心的模式提出了挑战。支付方和医疗系统正在探索基于价值的框架和按绩效付费的合约模式，这些模式强调实际疗效而非传统的手术量。这些变革要求製造商和医疗服务提供者证明其产品具有持续的临床效益，控制总医疗成本，并投资于长期实证医学研究。

最后，患者的期望和诉求已成为塑造研究重点和监管讨论的核心。患者要求治疗方法不仅要延长生存期，还要保护神经功能和生活质量，因此，人们越来越关注神经认知终点和支持性护理的整合。由此，相关人员必须应对一个更复杂、以病人为中心的环境，这需要灵活应变、跨部门合作和强而有力的实证策略。

深入分析 2025 年美国关税政策变化如何影响神经肿瘤治疗方法和医疗设备的供应链、筹资策略和存取动态。

2025年美国关税政策为脑癌和脊髓癌治疗治疗方法及医疗设备的采购、生产和整体全球筹资策略带来了新的考量。活性药物原料药、医疗设备及相关耗材的关税调整影响了成本结构，促使各企业重新评估供应商多元化和近岸外包方案。这些政策变化使企业更加关注最终落地成本，并奖励企业建立本地製造伙伴关係和加强合约保护。

供应链中断风险的增加凸显了库存可视性、多元化筹资策略以及关键物资（例如特效癌症治疗药物、植入式医疗设备和精准放射治疗组件）策略储备的重要性。製造商正透过重新设计物流网络、寻找替代供应商以及修订定价合约来应对这一挑战，以反映更高的进口成本和风险缓解投资。采购团队和财务负责人比以往任何时候都更加积极主动地进行情境规划，以量化关税对营运的影响，并确保患者照护的连续性。

监管机构和商业部门也需要考虑价格上涨对医疗服务取得和报销的潜在下游影响。支付者可能会透过调整药品目录策略和报销率来应对采购成本的上涨，而医疗服务提供者则可能面临利润率压力，这可能会影响新型高成本治疗方法的推广应用。因此，各机构应优先建立透明的供应商关係，倡导保护病患用药的政策机制，并制定以证据为基础的价值提案，使单价上涨与临床和经济效益相符。

高解析度分割分析揭示了肿瘤类型、治疗方法、患者人口统计特征、医疗机构和通路如何相互作用，从而决定临床和商业性优先事项。

基于细分市场的分析揭示了肿瘤生物学、治疗方法、年龄层、医疗环境和分销管道等方面的细微需求模式和策略重点。按癌症类型分類的市场分析涵盖星状细胞瘤、室管膜瘤、胶质母细胞瘤、髓母细胞瘤、脑膜瘤、少突胶质瘤和神经鞘瘤，每种癌症都有其独特的临床病程、生物标记特征和影响治疗方案的手术考量。按治疗方法划分，市场涵盖化疗、免疫疗法、放射线治疗、支持性治疗、手术和分子标靶治疗，其中化疗进一步细分为烷化剂、亚硝基脲类药物和含铂类药物。免疫疗法细分为CAR-T细胞疗法和查核点抑制剂；放射线治疗细分为体外放射疗法、质子疗法和立体定位放射线手术；手术则分为开颅手术、雷射消熔和微创切除术。标靶治疗的特点是使用激酶抑制剂和单株抗体。

患者的人口统计学特征对临床和商业性策略有显着影响。基于患者年龄组的分析区分了成人、老年人和儿童群体，从而揭示了肿瘤生物学、耐受性和长期生存需求方面的差异。这些因素决定了不同的证据要求和服务模式。基于最终用户，本研究检视了门诊手术中心、癌症诊所、居家照护机构和医院等不同医疗服务提供方式，反映了它们在实施复杂干预、处理併发症和协调多学科诊疗方面的不同能力。基于分销管道，本研究评估了诊所药房、医院药房、线上药房、零售药房和专科药房，并认识到通路选择会影响用药依从性、专科药物的可及性和患者援助计划。

整合这些细分观点，可以凸显组织应优先关注的交叉领域，例如：老年特定类型肿瘤患者的症状如何影响积极手术和全身治疗的适用性；儿童肿瘤生物学如何影响参与专科临床试验；放射治疗方法如何取决于肿瘤位置和患者年龄；以及分销渠道策略如何促进或限制药物依从性和居家支持护理计划。这些见解有助于开发针对性产品、产生实证医学证据并建立商业模式，以满足神经肿瘤治疗路径的多样化需求。

整合美洲、欧洲、中东和非洲以及亚太地区的临床能力、监管复杂性和准入驱动因素的区域情报，可协助您制定优先策略。

区域趋势对脑部和脊髓肿瘤先进疗法的可及性、临床能力和法规环境有显着影响。在美洲，综合性学术中心和专科癌症网络推动了新型外科技术和先进放射治疗方法的早期应用，而支付方的谈判和报销政策则决定了商业性推广的速度。区域内的跨国合作有助于临床试验的招募和知识交流，但都市区三级医疗中心和社区医疗机构之间仍存在可近性差异，影响着复杂疾病治疗的公平性。

儘管欧洲、中东和非洲地区（EMEA）已实现监管协调和区域采购机制，但各地区医疗系统能力仍有显着差异。资源丰富的欧洲市场已发展出精准诊断和质子治疗基础设施，而中东和北非（MENA）地区的部分地区则专注于基础设施建设、人才培养和扩大基本治疗的可及性。因此，策略伙伴关係、技术转移和能力建设倡议对于扩大这些市场的可近性至关重要。报销框架和国家政策重点将影响先进治疗方法的长期应用和永续性。

对肿瘤基础设施的快速投资以及对国内生物技术创新日益重视，正在加速亚太地区标靶治疗和先进放射治疗服务的普及。然而，不同的支付系统和监管路径造成了不同的市场准入考量。在许多地区，製造商必须应对复杂的当地报销标准、价格谈判以及公私合营，才能实现广泛的市场准入。在不同地区，相关人员必须根据当地的监管要求、临床实务规范和基础设施实际情况，调整证据产生、市场进入策略和生产决策。

竞争考察重点在于神经肿瘤学市场领导的创新组合、策略伙伴关係和实证商业化方法。

主要企业正透过标靶治疗、先进的放射治疗平台和支持性护理解决方案等产品组合来脱颖而出。一些清晰的策略行为模式显而易见：投资精准诊断以确保患者筛选的准确性；与学术机构合作以加速转化研究和临床试验招募；以及透过授权许可扩大地域覆盖范围并降低研发风险。此外，他们也日益垂直整合特种化合物和无菌注射剂的供应链，以降低供应中断的风险。

合作模式正从简单的共同开发契约演变为包含资料共用框架、合作进行的真实世界证据研究以及按绩效付费合约试点等多方面联盟。这些安排使各机构能够将报销与已证实的患者获益挂钩，并共用临床和财务风险。从商业角度来看，人们越来越关注患者支援服务、用于提高依从性的数位化互动工具以及中心辐射式分销模式，以满足复杂生物製药和细胞疗法的需求。

竞争优势日益依赖展现长期神经系统疗效和贯穿整个治疗过程的价值，而非单一疗效。因此，整合可靠的实证医学证据、灵活的定价模式以及与医疗服务提供者网路建立策略合作伙伴关係的公司策略，将更有利于实现持续的市场认可，同时满足支付方和患者的期望。

为产业领导者提供切实可行的优先建议，以加快治疗效果、加强供应链并扩大神经肿瘤治疗途径中的公平获取途径。

产业领导者应采取一套平衡的短期和长期措施，以应对临床影响、供应链韧性和公平取得等问题。优先投资生物标记项目和综合诊断，以确保精准筛选患者并最大限度地提高治疗效果。除了分子策略外，还应建立完善的註册登记和真实世界证据项目，以收集神经认知结果和长期生活品质指标，这些指标在医保报销讨论和临床医生采纳治疗方案方面发挥着日益重要的作用。

为降低关税和进口风险，应透过多元化经营、寻找替代供应商以及考虑建立区域製造伙伴关係关係来加强供应链。在采购惯例中，建立合约弹性和库存透明度至关重要，这有助于减轻政策变更带来的营运负担。在商业层面，应针对每个通路和医疗机构量身定制患者支援模式，确保在门诊和居家医疗环境中适当整合专业护理、用药依从性计划和远端监测。

最后，我们将建构一个涵盖产业、医疗服务提供者和病患权益倡议团体的协作生态系统，以加速临床试验招募、统一证据优先顺序并推动相关政策，从而保障商业性获得高价值疗法的机会。透过共同实施这些倡议，各组织可以将科学进步转化为永续的临床改善和永续成果。

我们采用透明、严谨的混合方法调查方法，结合文献综合、专家访谈和证据三角验证，以支持我们的策略结论并承认其局限性。

本分析采用混合方法设计，结合系统性的二手资料研究和针对性的原始研究，以检验并填补证据空白。二手资料来源包括同侪审查文献、临床试验註册库、监管文件和政策公告，全面展现了治疗机制、临床终点和监管先例。此文献回顾优先考虑高品质的随机对照试验、关键医疗设备评估和共识指引更新，以最可靠的证据支持临床解读。

初步研究包括对临床专家、医疗系统领导者、支付方代表和供应链专业人员的访谈，以收集他们对实施障碍、报销趋势和营运韧性的看法。专家见解被用于制定关税影响、采购应对措施和区域产能限制的情境计画。证据综合分析采用主题编码来协调相互衝突的观点，并突显策略行动的优先领域，而敏感度分析则揭示了各种依赖关係和潜在限制。

此调查方法的局限性包括监管决策的流动性以及临床数据快速发展可能导致实践模式发生变化。为弥补这些局限性，该调查方法在假设方面保持透明，明确指出关键输入资料的获取时间，并识别需要持续监测和定期更新的领域，以保持其策略相关性。

一项重要的综合分析，重点强调了临床创新、营运韧性和协调政策行动之间相互依存的优先事项，以改善神经肿瘤学的治疗效果。

科学创新、医疗服务模式演变和政策转变的交会动态，要求神经肿瘤学生态系统各部门协同应对。精准诊断和新型治疗方法有望显着提高患者存活率并保护神经功能，但要实现这一目标，需要强有力的循证策略、稳健的供应链和公平的医疗资源获取机制。因此，相关人员必须将临床研发与真实世界证据的生成结合，儘早与支付方接洽，并以病人和医疗系统都能理解的方式清晰阐述其价值。

在营运层面，各机构应着重于供应链多元化、策略性製造伙伴关係关係以及能够保障病患治疗连续性的采购惯例，同时应对政策波动。针对不同地区的监管路径、基础设施和报销模式，需要製定区域性策略。商业性成功将日益依赖整合式服务模式，将治疗与诊断、病患支持服务和数位化工具结合，以提高病患依从性和治疗效果。

摘要，要将进展转化为持续改进，需要从系统层面观点，平衡创新与实施。透过优先考虑证据生成、营运韧性和协作参与，相关人员可以加速显着改善脑脊髓肿瘤患者的治疗效果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • CAR-T细胞疗法在復发性多形性胶质母细胞瘤的应用日益广泛，并提高了患者的存活率。
  • 将人工智慧驱动的放射组学和机器学习相结合，用于中枢神经系统癌症的精准诊断和治疗计划。
  • 开发聚焦超音波技术，以暂时破坏血脑障壁，从而实现胶质母细胞瘤的标靶药物传递。
  • 增加对基于奈米颗粒的药物递送系统的投资，以增强脊椎肿瘤治疗的标靶化
  • 增加肿瘤治疗的使用可改善新诊断胶质母细胞瘤患者的无恶化生存期
  • 利用循环肿瘤DNA拓展液态生物检体在脑转移瘤早期检测与后续观察的应用
  • 针对IDH1突变的基因编辑方法在少突胶质细胞瘤和低度胶质瘤的治疗研发中崭露头角
  • 生物技术公司与学术机构之间的合作正在不断扩大，以开髮用于治疗中枢神经系统恶性肿瘤的新型免疫疗法疫苗。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依癌症类型分類的脑部和脊髓癌市场

  • 星状细胞瘤
  • 室管膜瘤
  • 胶质母细胞瘤
  • 髓母细胞瘤
  • 脑膜瘤
  • 少突胶质细胞
  • 神经鞘瘤

第九章 依治疗方式分類的脑部和脊髓癌市场

  • 化疗
    • 烷化剂
    • 亚硝基脲
    • 含铂类药物
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
  • 放射治疗
    • 体外放射治疗
    • 质子治疗
    • 立体定位放射放射线手术
  • 支持性护理
  • 外科手术
    • 开颅手术
    • 雷射消熔
    • 微创切除术
  • 标靶治疗
    • 激酶抑制剂
    • 单株抗体

第十章 依患者年龄层分類的脑部和脊髓癌市场

  • 成人版
  • 老年人
  • 孩子们

第十一章 依最终用户分類的脑部和脊髓癌市场

  • 门诊手术中心
  • 癌症诊所
  • 居家医疗环境
  • 医院

第十二章 脑和脊髓癌市场按通路划分

  • 诊所药房
  • 医院药房
  • 网路药房
  • 零售药房
  • 专卖店

第十三章 脑和脊髓癌市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 脑和脊髓癌市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国脑和脊髓癌市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • AbbVie Inc.
    • Bayer AG
    • Novocure Limited
    • Eisai Co., Ltd.
Product Code: MRR-9E71DF483B96

The Brain & Spinal Cord Cancer Market is projected to grow by USD 6.33 billion at a CAGR of 5.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.98 billion
Estimated Year [2025] USD 4.21 billion
Forecast Year [2032] USD 6.33 billion
CAGR (%) 5.97%

A strategic introduction to the converging clinical, regulatory, and operational forces that are reshaping diagnosis, treatment, and care delivery in neuro-oncology

This executive summary distills the most consequential clinical, operational, and strategic themes shaping care for brain and spinal cord cancers. Advances in molecular characterization and precision therapeutics have redefined diagnostic pathways while concurrently introducing new complexity into treatment decision-making. At the same time, evolving care-delivery models and greater emphasis on multidisciplinary coordination are shifting how patients experience diagnosis, treatment, and survivorship.

Regulatory pathways are evolving in parallel, with accelerated approvals and adaptive trial designs enabling earlier patient access to novel interventions. These innovations come with heightened requirements for real-world evidence and post-approval data that stakeholders must integrate into lifecycle planning. Equally important are the system-level forces-supply chain fragility, workforce constraints, and payment policy debates-that influence how innovations translate into practice.

Taken together, these dynamics create both opportunity and responsibility for commercial teams, clinical leaders, and payers. This summary presents a structured view of the transformational shifts, tariff-driven supply considerations, segmentation-driven insights, regional distinctions, and competitive behaviors that should inform strategy and investment priorities across the neuro-oncology ecosystem.

A clear-eyed review of the transformative scientific, care-delivery, and policy shifts that are redefining neuro-oncology treatment paradigms and stakeholder expectations

Therapeutic innovation is the most visible driver of change, with targeted agents, immunotherapies, and advanced radiation modalities altering conventional treatment algorithms. Precision diagnostics now stratify patients into molecularly defined cohorts, enabling more personalized regimens but also requiring integrated biomarker testing infrastructure and new care pathways. These scientific advances are complemented by procedural and device improvements, including safer surgical techniques and more precise stereotactic delivery systems, which together reduce morbidity and expand treatment candidacy.

Care delivery is undergoing a parallel transformation. Multidisciplinary tumor boards, virtual care modalities, and decentralized treatment options are increasing access while challenging traditional hospital-centric models. Payers and health systems are experimenting with value-based frameworks and outcomes-based contracting, which emphasize real-world outcomes over traditional procedural volumes. These shifts force manufacturers and providers to demonstrate sustained clinical benefit, manage total cost of care, and invest in longitudinal evidence generation.

Finally, patient expectations and advocacy voices now play a central role in shaping research priorities and regulatory conversations. Patients seek therapies that not only extend survival but preserve neurologic function and quality of life, prompting greater attention to neurocognitive endpoints and supportive care integration. As a result, stakeholders must navigate a more complex, patient-centered landscape that demands agility, cross-sector partnerships, and robust evidence strategies.

An incisive assessment of how United States tariff policy changes in 2025 are reshaping supply chains, sourcing strategies, and access dynamics for neuro-oncology therapies and devices

United States tariff policies enacted in 2025 have introduced new considerations across procurement, manufacturing, and global sourcing strategies for therapies and devices used in brain and spinal cord cancer care. Tariff adjustments on active pharmaceutical ingredients, medical devices, and ancillary supplies affect cost structures and have prompted organizations to reassess supplier diversification and nearshoring options. These policy changes heightened attention to total landed cost and created incentives for local manufacturing partnerships and contractual protections.

Supply chain disruption risk has increased the premium on inventory visibility, multi-sourcing strategies, and strategic stockpiles for critical items such as specialty oncology drugs, implantable devices, and precision radiation components. Manufacturers are responding by redesigning logistics networks, qualifying alternate suppliers, and revising pricing contracts to reflect increased import costs and mitigation investments. Procurement teams and finance leaders are now more actively engaging in scenario planning to quantify tariff-related operational impacts and ensure continuity of patient care.

Regulatory and commercial teams must also account for potential downstream effects on access and reimbursement. Payers may adjust formulary strategies or reimbursement rates in response to higher acquisition costs, while providers could face pressure on margins that affects adoption of newer, higher-cost modalities. Therefore, organizations should prioritize transparent supplier relationships, advocate for policy mechanisms that protect patient access, and develop evidence-based value propositions that reconcile higher unit costs with clinical and economic outcomes.

High-resolution segmentation insights revealing how tumor types, therapeutic modalities, patient age cohorts, care settings, and distribution channels jointly determine clinical and commercial priorities

Segmentation-driven analysis reveals nuanced demand patterns and strategic priorities across tumor biology, therapeutic modality, age demographics, care settings, and distribution channels. Based on Cancer Type, market analysis covers Astrocytoma, Ependymoma, Glioblastoma, Medulloblastoma, Meningioma, Oligodendroglioma, and Schwannoma, each presenting distinct clinical courses, biomarker profiles, and surgical considerations that inform therapeutic choices. Based on Treatment Type, the landscape spans Chemotherapy, Immunotherapy, Radiation Therapy, Supportive Care, Surgery, and Targeted Therapy, with chemotherapy further detailed into Alkylating Agents, Nitrosoureas, and Platinum Based Agents; immunotherapy delineated into CAR T Cell Therapy and Checkpoint Inhibitors; radiation therapy separated into External Beam Radiation, Proton Therapy, and Stereotactic Radiosurgery; surgery differentiated by Craniotomy, Laser Ablation, and Minimally Invasive Resection; and targeted therapy characterized by Kinase Inhibitors and Monoclonal Antibodies.

Patient demographics materially influence clinical and commercial approaches. Based on Patient Age Group, the analysis distinguishes Adult, Geriatric, and Pediatric populations, capturing differences in tumor biology, tolerability, and long-term survivorship needs that drive distinct evidence requirements and service models. Based on End User, care delivery is examined across Ambulatory Surgical Centers, Cancer Clinics, Home Care Settings, and Hospitals, reflecting varied capabilities for delivering complex interventions, managing complications, and coordinating multidisciplinary care. Based on Distribution Channel, the study assesses Clinic Pharmacies, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Stores, recognizing that channel choice affects adherence, specialty drug handling, and patient support programs.

Integrating these segmentation lenses highlights intersections that organizations must prioritize: for example, how geriatric presentations of specific tumor types alter suitability for aggressive surgery or systemic therapy; how pediatric tumor biology drives enrollment in specialized trials; how selection of radiation modality depends on tumor location and patient age; and how distribution channel strategies can either enable or constrain adherence and home-based supportive care programs. These insights support targeted product development, evidence generation, and commercial models that align with the heterogeneous needs across neuro-oncology care pathways.

Regional intelligence synthesizing clinical capacity, regulatory complexity, and access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform prioritized strategies

Regional dynamics materially influence clinical capacity, regulatory environments, and access to advanced therapies for brain and spinal cord cancers. In the Americas, integrated academic centers and specialized cancer networks often drive early adoption of novel surgical techniques and advanced radiation modalities, while payer negotiations and reimbursement policy shape the pace of commercial uptake. Cross-border collaboration within the region supports clinical trial enrollment and knowledge exchange, but disparities in access persist between urban tertiary centers and community providers, which affects equitable delivery of complex care.

In Europe, Middle East & Africa, regulatory harmonization and regional procurement mechanisms coexist with widely varying health system capacities. High-resource European markets exhibit strong capabilities for precision diagnostics and proton therapy infrastructure, whereas parts of the Middle East and Africa emphasize capacity building, workforce development, and access to essential therapies. Strategic partnerships, technology transfer, and capacity-strengthening initiatives are therefore central to expanding access in these markets. Reimbursement frameworks and national policy priorities influence long-term adoption and the sustainability of advanced modalities.

In the Asia-Pacific region, rapid investments in oncology infrastructure and a growing emphasis on domestic biotech innovation are accelerating availability of targeted agents and advanced radiation services. However, heterogeneous payer systems and regulatory pathways create varying commercial entry considerations. In many jurisdictions, manufacturers must navigate complex local reimbursement criteria, pricing negotiations, and public-private partnerships to achieve broad access. Across regions, stakeholders should tailor evidence generation, access strategies, and manufacturing decisions to reflect local regulatory expectations, clinical practice norms, and infrastructure realities.

Competitive company insights emphasizing innovation portfolios, strategic partnerships, and evidence-driven commercialization approaches that differentiate market leaders in neuro-oncology

Leading companies in the neuro-oncology space are differentiating through integrated portfolios that combine targeted agents, advanced radiation platforms, and supportive care solutions. Strategic behaviors fall into several observable patterns: investment in precision diagnostics to ensure appropriate patient selection; partnerships with academic centers to accelerate translational research and trial enrollment; and licensing agreements that expand geographic reach while mitigating development risk. Firms are also pursuing vertical integration in supply chains for specialty compounds and sterile injectable formulations to reduce disruption risk.

Collaboration models are evolving from simple co-development agreements to multifaceted alliances that include data-sharing frameworks, joint real-world evidence initiatives, and outcomes-based contracting pilots. These arrangements allow organizations to align reimbursement with demonstrated patient benefit and to share both clinical and financial risk. From a commercialization perspective, companies are placing greater emphasis on patient support services, digital engagement tools to improve adherence, and hub-and-spoke distribution models that accommodate the handling needs of complex biologics and cell therapies.

Competitive differentiation increasingly depends on demonstrating long-term neurologic outcomes and value across care episodes rather than single-point efficacy. As a result, corporate strategies that integrate robust evidence generation, adaptive pricing models, and strategic partnerships with provider networks will be better positioned to capture sustained uptake while addressing payer and patient expectations.

Practical and prioritized recommendations for industry leaders to accelerate therapeutic impact, fortify supply chains, and expand equitable access within neuro-oncology care pathways

Industry leaders should pursue a balanced set of near-term and long-term actions that address clinical impact, supply chain resilience, and equitable access. Prioritize investment in biomarker programs and integrated diagnostics to ensure precise patient selection and to maximize therapeutic benefit. Complement molecular strategies with robust registries and real-world evidence programs that capture neurocognitive outcomes and longitudinal quality-of-life measures, which are increasingly central to reimbursement discussions and clinician adoption.

Strengthen supply chains through diversification, qualification of alternate suppliers, and consideration of regional manufacturing partnerships to mitigate tariff and import risks. Build contractual flexibility and inventory visibility into procurement practices to reduce the operational strain of policy shifts. On the commercial front, design patient support models that align with distinct distribution channels and care settings, ensuring that specialty handling, adherence programs, and remote monitoring are embedded within the ambulatory and home-care contexts where appropriate.

Finally, cultivate collaborative ecosystems across industry, providers, and patient advocacy groups to accelerate trial enrollment, align evidence priorities, and advocate for policies that preserve access to high-value interventions. Implementing these steps in concert will enable organizations to convert scientific advances into durable clinical improvements and sustainable commercial outcomes.

A transparent and rigorous mixed-methods research approach that combines literature synthesis, expert interviews, and evidence triangulation to underpin strategic conclusions and acknowledge limitations

The analysis integrates a mixed-methods research design that pairs systematic secondary research with targeted primary engagements to validate findings and fill evidence gaps. Secondary sources included peer-reviewed literature, clinical trial registries, regulatory documents, and policy releases to construct a comprehensive view of therapeutic mechanisms, clinical endpoints, and regulatory precedents. This literature synthesis prioritized high-quality randomized trials, pivotal device evaluations, and consensus guideline updates to ground clinical interpretations in the strongest available evidence.

Primary research comprised interviews with clinical experts, health system leaders, payer representatives, and supply chain professionals to elicit perspectives on adoption barriers, reimbursement dynamics, and operational resilience. Expert input informed scenario planning around tariff impacts, procurement responses, and regional capacity constraints. Evidence synthesis applied thematic coding to reconcile divergent viewpoints and to surface priority areas for strategic action, while sensitivity assessments highlighted dependencies and potential limitations.

Limitations of the methodology include the evolving nature of regulatory decisions and rapidly emerging clinical data that may alter practice patterns. To mitigate these constraints, the study emphasizes transparent assumptions, documents data vintage for key inputs, and identifies areas where ongoing surveillance and periodic updates will be necessary to maintain strategic relevance.

A conclusive synthesis that emphasizes the interdependent priorities of clinical innovation, operational resilience, and collaborative policy action necessary to improve neuro-oncology outcomes

The convergent forces of scientific innovation, evolving care delivery, and shifting policy require coordinated responses across the neuro-oncology ecosystem. Precision diagnostics and novel therapeutics offer genuine promise for improving survival and preserving neurologic function, yet realizing that promise depends on robust evidence strategies, resilient supply chains, and equitable access frameworks. Stakeholders must therefore align clinical development with real-world evidence generation and engage payers early to articulate value in terms that matter to patients and health systems.

Operationally, organizations should focus on supply chain diversification, strategic manufacturing partnerships, and procurement practices that absorb policy shocks while protecting patient continuity of care. Region-specific strategies will be necessary to reflect heterogeneity in regulatory pathways, infrastructure, and reimbursement models. Commercial success will increasingly hinge on integrated offers that combine therapeutics with diagnostics, patient support services, and digital tools that facilitate adherence and outcome measurement.

In summary, transforming advances into durable improvements requires a systems-level perspective that balances innovation with practical implementation. By prioritizing evidence generation, operational resilience, and collaborative engagement, stakeholders can accelerate meaningful improvements in outcomes for people affected by brain and spinal cord cancers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of CAR T-cell therapies for recurrent glioblastoma multiforme improving survival outcomes
  • 5.2. Integration of AI-driven radiomics and machine learning for precision diagnosis and treatment planning in CNS cancers
  • 5.3. Development of focused ultrasound techniques to transiently disrupt the blood-brain barrier for targeted drug delivery in gliomas
  • 5.4. Increasing investment in nanoparticle-based drug delivery systems for spinal cord tumor therapeutics with enhanced targeting
  • 5.5. Expansion of tumor treating fields therapy utilization in newly diagnosed glioblastoma patients to extend progression free survival
  • 5.6. Rise of liquid biopsy applications using circulating tumor DNA for early detection and monitoring of brain metastases
  • 5.7. Emergence of gene editing approaches targeting IDH1 mutations in oligodendroglioma and low-grade glioma treatment pipelines
  • 5.8. Growing collaboration between biotech firms and academic centers for novel immunotherapeutic vaccine development in CNS malignancies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain & Spinal Cord Cancer Market, by Cancer Type

  • 8.1. Astrocytoma
  • 8.2. Ependymoma
  • 8.3. Glioblastoma
  • 8.4. Medulloblastoma
  • 8.5. Meningioma
  • 8.6. Oligodendroglioma
  • 8.7. Schwannoma

9. Brain & Spinal Cord Cancer Market, by Treatment Type

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Nitrosoureas
    • 9.1.3. Platinum Based Agents
  • 9.2. Immunotherapy
    • 9.2.1. CAR T Cell Therapy
    • 9.2.2. Checkpoint Inhibitors
  • 9.3. Radiation Therapy
    • 9.3.1. External Beam Radiation
    • 9.3.2. Proton Therapy
    • 9.3.3. Stereotactic Radiosurgery
  • 9.4. Supportive Care
  • 9.5. Surgery
    • 9.5.1. Craniotomy
    • 9.5.2. Laser Ablation
    • 9.5.3. Minimally Invasive Resection
  • 9.6. Targeted Therapy
    • 9.6.1. Kinase Inhibitors
    • 9.6.2. Monoclonal Antibodies

10. Brain & Spinal Cord Cancer Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Brain & Spinal Cord Cancer Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cancer Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Brain & Spinal Cord Cancer Market, by Distribution Channel

  • 12.1. Clinic Pharmacies
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies
  • 12.5. Specialty Stores

13. Brain & Spinal Cord Cancer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain & Spinal Cord Cancer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain & Spinal Cord Cancer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. F. Hoffmann-La Roche Ltd
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. Bristol-Myers Squibb Company
    • 16.3.6. AstraZeneca PLC
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Bayer AG
    • 16.3.9. Novocure Limited
    • 16.3.10. Eisai Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN & SPINAL CORD CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SI